Literature DB >> 10348468

Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale.

P Hagell1, H Widner.   

Abstract

Drug-induced dyskinesias (DID) manifested as hyperkinetic and/or dystonic movements or postures are common problems in Parkinson's disease (PD). Novel therapeutic interventions may offer possibilities to counteract these common adverse effects of an otherwise necessary treatment. To be able to evaluate the effects of such interventions on DID, reliable and relevant clinical assessment tools are needed. We tested the inter- and intrarater reliability of a new clinical dyskinesia rating scale consisting of separate ratings of different body parts, including lateralization and separate ratings of dystonia and hyperkinesias. Interrater reliability was tested both with and without a defined scoring code and clarification of the dystonia section. The nondefined version was also tested for intrarater reliability. Thirteen raters independently reviewed 23 videotape sequences showing PD patients performing standardized motor tests. Inter- and intrarater agreement was significant in all evaluations, and no differences were detected when comparing ratings performed with the defined and nondefined version of the scale. The rationale for, and the role and use of, the present scale are addressed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348468     DOI: 10.1002/1531-8257(199905)14:3<448::aid-mds1010>3.0.co;2-0

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Slow (1 Hz) repetitive transcranial magnetic stimulation (rTMS) induces a sustained change in cortical excitability in patients with Parkinson's disease.

Authors:  Sasa R Filipović; John C Rothwell; Kailash Bhatia
Journal:  Clin Neurophysiol       Date:  2010-03-28       Impact factor: 3.708

2.  Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia.

Authors:  Marina Picillo; Gustavo B Vincos; Drew S Kern; Susan H Fox; Anthony E Lang; Alfonso Fasano
Journal:  Mov Disord Clin Pract       Date:  2015-10-27

3.  Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Elaine Bandeira Cavalcanti Duarte; Laura Maria Ramos Miranda; Andore Guescel C Asano; Nadja Maria Jorge Asano; Maria de Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Neuromolecular Med       Date:  2019-05-22       Impact factor: 3.843

4.  Objective measurement of dyskinesia in Parkinson's disease using a force plate.

Authors:  Kathryn A Chung; Brenna M Lobb; John G Nutt; James McNames; Fay Horak
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

5.  Paroxysmal dyskinesias in mice.

Authors:  Thomas L Shirley; Lekha M Rao; Ellen J Hess; H A Jinnah
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

6.  Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.

Authors:  T R K Varma; S H Fox; P R Eldridge; P Littlechild; P Byrne; A Forster; A Marshall; H Cameron; K McIver; N Fletcher; M Steiger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 7.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

8.  Use and interpretation of on/off diaries in Parkinson's disease.

Authors:  J Reimer; M Grabowski; O Lindvall; P Hagell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

9.  Supervised versus unsupervised technology-based levodopa monitoring in Parkinson's disease: an intrasubject comparison.

Authors:  Giovanna Lopane; Sabato Mellone; Mattia Corzani; Lorenzo Chiari; Pietro Cortelli; Giovanna Calandra-Buonaura; Manuela Contin
Journal:  J Neurol       Date:  2018-03-29       Impact factor: 4.849

10.  Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.

Authors:  Giovanna Calandra-Buonaura; Andrea Doria; Giovanna Lopane; Pietro Guaraldi; Sabina Capellari; Paolo Martinelli; Pietro Cortelli; Manuela Contin
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.